Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Summary Glucagonlike peptide1 (GLP1) receptor agonists (RAs) are an important class
of drugs with a wellestablished efficacy and safety profile in patients with type 2 diabetes …

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

Background It is estimated that 29.1 million people or 9.3% of the US population have
diabetes, which contributes to considerable medical and financial burden. Type 2 diabetes …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for
treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes …

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

More than 26 million people in the United States have type 2 diabetes mellitus (T2D). Many
treatment options exist, but achieving longterm glycemic control in patients with T2D …

The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents
used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established as effective
treatments for patients with type 2 diabetes. GLP-1 RAs augment insulin secretion and …

ABSTRACT Glucagon-like peptide-1 (GLP-1) is a hormone of the incretin system
responsible for a variety of glucoregulatory effects, including glucose-dependent secretion of …